Search

Your search keyword '"Ware, James H."' showing total 317 results
Start Over Author "Ware, James H." Language english
317 results on '"Ware, James H."'

6. Effects of Lead Exposure

Author

Ernhart, Claire B., Rogan, Walter J., Ware, James H., Dietrich, Kim N., Radcliffe, Jerilynn, and Rhoads, George G.

Published
2001

13. Large lipid-rich coronary plaques detected by near-infrared spectroscopy at non-stented sites in the target artery identify patients likely to experience future major adverse cardiovascular events

Author

Madder, Ryan D., Husaini, Mustafa, Davis, Alan T., VanOosterhout, Stacie, Khan, Mohsin, Wohns, David, McNamara, Richard F., Wolschleger, Kevin, Gribar, John, Collins, J. Stewart, Jacoby, Mark, Decker, Jeffrey M., Hendricks, Michael, Sum, Stephen T., Madden, Sean, Ware, James H., and Muller, James E.

Published
2016
Full Text
View/download PDF

14. Comparison of Catheterization Laboratory Initiated Abciximab and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes (an ACUITY Substudy)

Author

Kirtane, Ajay J., Parise, Helen, Mehran, Roxana, Moses, Jeffrey W., Fahy, Martin, Bertrand, Michel E., Ohman, E. Magnus, White, Harvey D., Feit, Frederick, Colombo, Antonio, McLaurin, Brent T., Cox, David A., Ware, James H., Pocock, Stuart J., Lansky, Alexandra J., and Stone, Gregg W.

Published
2010
Full Text
View/download PDF

41. Influence of Timing of Clopidogrel Treatment on the Efficacy and Safety of Bivalirudin in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: An Analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial

Author

Lincoff, A. Michael, Steinhubl, Steven R., Manoukian, Steven V., Chew, Derek, Pollack, Charles V., Jr, Feit, Frederick, Ware, James H., Bertrand, Michel E., Ohman, E. Magnus, Desmet, Walter, Cox, David A., Mehran, Roxana, and Stone, Gregg W.

Published
2008
Full Text
View/download PDF

44. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial

Author

Stone,Gregg W., Ware, James H., Bertrand, Michel E., Lincoff, A. Michael, Moses, Jeffrey W., Ohman, F. Magnus, White, Harvey D., Feit, Frederick, Colombo, Antonio, McLaurin, Brent T., Cox, David A., Manoukian, Steven W., Fahy, Martin, Clayton, Tim C., Mehran, Roxana, and Pocock, Stuart J.

Subjects
Coronary heart disease -- Drug therapy, Coronary heart disease -- Care and treatment, Thrombolytic drugs -- Patient outcomes
Abstract

A study to determine 1-year ischemic or mortality outcomes for patients in the ACUITY trial is presented. Results conclude with no significant difference in mortality rates among patients with moderate and high-risk ACS undergoing invasive treatment.

Published
2007

45. Statistics in medicine-reporting of subgroup analyses in clinical trials

Author

Rui Wang, Lagakos, Stephen W., Ware, James H., Hunter, David J., and Drazen, Jeffrey M.

Subjects
Government regulation, Clinical trials -- Methods, Clinical trials -- Laws, regulations and rules
Abstract

The challenges related to conducting and reporting subgroup analyses are discussed.

Published
2007

46. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial

Author

Stone, Gregg W., White, Harvey D., Ohman, E. Magnus, Bertrand, Michel E., Lincoff, A. Michael, McLaurin, Brent T., Cox, David A., Pocock, Stuart J., Ware, James H., Feit, Frederick, Colombo, Antonio, Manoukian, Steven V., Lansky, Alexandra J., Mehran, Roxana, and Moses, Jeffrey W.

Subjects
Bivalirudin -- Dosage and administration, Bivalirudin -- Research, Heart attack -- Care and treatment, Heart attack -- Research, Angioplasty -- Patient outcomes
Published
2007

47. Bivalirudin for patients with acute coronary syndromes

Author

Stone, Gregg W.; McLaurin, Brent T.; Cox, David A., Bertrand, Michel E.; Lincoff, Michael, Moses, Jeffrey W.; White, Harvey D.; Pocock, Stuart J., Ware, James H.; Feit, Frederick, Colombo, Antonio; Aylward, Philip E.; Cequier, Angel R., Darius, Harald; Desmet, Walter, Ebrahimi, Ramin; Hamon, Martial; Rasmussen, Lars H., Rupprecht, Hans-Jurgen; Hoekstra, James; Mehran, Roxana, and Ohman, E. Magnus

Subjects
Coronary heart disease -- Drug therapy, Blood platelets -- Aggregation, Blood platelets -- Evaluation
Abstract

A study was conducted to evaluate the usefulness of bivalirudin as part of an early invasive strategy with optimal antiplatelet therapy in patients with acute coronary syndromes. It was found that in patients with unstable angina or myocardial infarction without ST-segment elevation who were undergoing early invasive management, the rates of ischemic events and bleeding were similar with the use of either bivalirudin or heparin when combined with the planned use of a glycoprotein IIb/IIIa inhibitor.

Published
2006

48. Physical activity, including walking, and cognitive function in older women

Author

Weuve, Jennifer, Jae Hee Kang, Manson, Joann E., Breteler, Monique M.B., Ware, James H., and Grodstein, Francine

Subjects
Walking -- Psychological aspects, Walking -- Health aspects, Exercise -- Psychological aspects, Exercise -- Health aspects, Aged women -- Health aspects, Aged women -- Psychological aspects, Dementia -- Risk factors, Dementia -- Demographic aspects, Dementia -- Prevention
Abstract

Research shows that regular, long-term physical activity is linked to better cognitive function in elderly women, and may help prevent cognitive decline. Physical activity includes walking. data are drawn from 18,766 women from 70 to 81 years of age in the United States.

Published
2004

49. Effect of chelation therapy on the neuropsychological and behavioral development of lead-exposed children after school entry

Author

Dietrich, Kim N., Ware, James H., Salganik, Mikhail, Radcliffe, Jerilynn, Rogan, Walter J., Rhoads, George G., Fay, Martha E., Davoli, Cecilia T., Denckla, Martha B., Bornschein, Robert L., Schwarz, Donald, Dockery, Douglas W., Adubato, Susan, and Jones, Robert L.

Subjects
Poisoning -- Care and treatment, Lead poisoning -- Care and treatment, Children -- Health aspects, Chelation therapy -- Health aspects
Abstract

Objective. Some children in the United States continue to be exposed to levels of lead that increase their risk for lowered intellectual functioning and behavior problems. It is unclear whether chelation therapy can prevent or reverse the neurodevelopmental sequelae of lead toxicity. The objective of this study was to determine whether chelation therapy with succimer (dimercaptosuccinic acid) in children with referral blood lead levels between 20 and 44 [micro]g/dL (0.96-2.12 [micro]mol/L) at 12 to 33 months of age has neurodevelopmental benefits at age 7 years. Methods. The Treatment of Lead-Exposed Children (TLC) study is a randomized, double-blind, placebo-controlled trial that was conducted between September 1994 and June 2003 in Philadelphia, PA; Newark, NJ; Cincinnati, OH; and Baltimore, MD. Of 1854 referred children who were between the ages of 12 to 33 months and screened for eligibility, 780 were randomized to the active drug and placebo groups stratified by clinical center, body surface area, blood lead level, and language spoken at home. At 7 years of age, 647 subjects remained in the study. Participants were randomly assigned to receive oral succimer or placebo. Up to 3 26-day courses of succimer or placebo therapy were administered depending on response to treatment in those who were given active drug. Eighty-nine percent had finished treatment by 6 months, with all children finishing by 13 months after randomization. All participants received residential lead hazard control measures before treatment. TLC subjects also received a daily multivitamin supplement before and after treatment(s) with succimer or placebo. Scores on standardized neuropsychological measures that tap cognition, behavior, learning and memory, attention, and neuromotor skills were measured. Results. Chelation therapy with succimer lowered average blood lead levels for ~6 months but resulted in no benefit in cognitive, behavioral, and neuromotor endpoints. Conclusion. These new follow-up data confirm our previous finding that the TLC regimen of chelation therapy is not associated with neurodevelopmental benefits in children with blood lead levels between 20 and 44 [micro]g/dL (0.96-2.17 [micro]mol/L). These results emphasize the importance of taking environmental measures to prevent exposure to lead. Chelation therapy with succimer cannot be recommended for children with blood lead levels between 20 and 44 [micro]g/dL (0.96-2.12 [micro]mol/L). Pediatrics 2004;114:19-26; child, lead, environmental exposure, chelation therapy, succimer, cognition, clinical trials. ABBREVIATIONS. CDC, Centers for Disease Control and Prevention; TLC, Treatment of Lead-Exposed Children; NEPSY, Developmental Neuropsychological Assessment; CI, confidence interval., Before the availability of chelating drugs, as many as 45% of lead-poisoned children who presented with signs or symptoms of encephalopathy died, and more than one quarter of surviving patients [...]

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results